LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Sanofi

Cerrado

50.48 1.96

Resumen

Variación precio

24h

Actual

Mínimo

50.13

Máximo

50.55

Métricas clave

By Trading Economics

Ingresos

1.4B

1.9B

Ventas

3B

11B

P/B

Media del Sector

17.382

51.198

BPA

1.022

Rentabilidad por dividendo

4.5

Margen de beneficio

17.65

Empleados

82,878

EBITDA

2.2B

2.8B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+23.24% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.50%

2.40%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-17B

121B

Apertura anterior

48.52

Cierre anterior

50.48

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Sanofi Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 jun 2025, 16:05 UTC

Principales Movimientos del Mercado

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2 jun 2025, 09:17 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 jun 2025, 05:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

22 may 2025, 12:02 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

22 may 2025, 00:06 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Vigil Neuroscience for About $470 Million

2 jun 2025, 13:50 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 jun 2025, 12:33 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

2 jun 2025, 10:50 UTC

Adquisiciones, fusiones, absorciones

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 jun 2025, 10:05 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 jun 2025, 05:06 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 jun 2025, 05:06 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 jun 2025, 05:05 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 jun 2025, 05:05 UTC

Adquisiciones, fusiones, absorciones

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 jun 2025, 05:04 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 jun 2025, 05:04 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2 jun 2025, 05:03 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Blueprint Medicines Corporation

2 jun 2025, 05:02 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Acquire Blueprint Medicines Corporation

30 may 2025, 08:58 UTC

Acciones populares

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 may 2025, 08:56 UTC

Charlas de Mercado

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

27 may 2025, 05:03 UTC

Adquisiciones, fusiones, absorciones

Sanofi Closes Acquisition of DR-0201 From Dren Bio

27 may 2025, 05:00 UTC

Adquisiciones, fusiones, absorciones

Press Release: Sanofi Completes Acquisition Of DR-0201 >SAN.FR

21 may 2025, 23:33 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 may 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 may 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 may 2025, 23:23 UTC

Adquisiciones, fusiones, absorciones

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 may 2025, 23:22 UTC

Adquisiciones, fusiones, absorciones

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 may 2025, 23:20 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 may 2025, 23:18 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

12 may 2025, 12:07 UTC

Charlas de Mercado

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

8 may 2025, 17:55 UTC

Ganancias

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

Comparación entre iguales

Cambio de precio

Sanofi Esperado

Precio Objetivo

By TipRanks

23.24% repunte

Estimación a 12 meses

Media 62.2 USD  23.24%

Máximo 67 USD

Mínimo 56 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

2

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

51.665 / 52.38Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.